AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
- Interventions
- Drug: AZD9291 tabletsProcedure: Pharmacokinetic sampling - AZD9291Other: Dietary FastedOther: Dietary High FatProcedure: Pharmacokinetic sampling - AZ5140 and AZ7550
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT02163733
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- Drug: AZD9291 tablet dosingProcedure: Pharmacokinetic sampling - AZD9291Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT02161770
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
Phase 3
Completed
- Conditions
- Uncontrolled Asthma
- Interventions
- Biological: TralokinumabOther: Placebo
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1207
- Registration Number
- NCT02161757
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- COPD Patients
- Interventions
- Other: Placebo for Symbicort pMDIOther: Placebo for Formoterol Turbohaler
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2026
- Registration Number
- NCT02157935
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
Phase 1
Completed
- Conditions
- Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT02157883
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo tablet
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 266
- Registration Number
- NCT02157298
- Locations
- 🇯🇵
Research Site, Yokohama-shi, Japan
Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 343
- Registration Number
- NCT02157376
- Locations
- 🇨🇳
Research Site, Zhanjiang, China
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT02155881
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
Phase 3
Completed
- Conditions
- Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2255
- Registration Number
- NCT02155660
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Non-Interventional Study PREVENT
Completed
- Conditions
- Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT02155998
- Locations
- 🇷🇺
Research Site, Vladimir, Russian Federation